调节性B淋巴细胞在乳腺癌进展中的临床意义  

The clinical significance of regulatory B lymphocytes in the progression of breast cancer

作　　者：张英[1] 邵华[1] 刘忠伦[2] 赵长新[1] ZHANG Ying;SHAO Hua;LIU Zhonglun;ZHAO Changxin(Department of Clinical Laboratory,Lianyungang Second People's Hospital,Lianyungang 222002,China;Department of Dermatosis,Lianyungang First People's Hospital,Lianyungang,China)

机构地区：[1]连云港市第二人民医院检验科,222002 [2]连云港市第一人民医院皮肤病实验室,222002

出　　处：《免疫学杂志》2019年第2期163-166,共4页Immunological Journal

基　　金：江苏省连云港市科技局医学检验科重点学科建设项目(SH1526)

摘　　要：目的检测乳腺癌患者和健康对照者外周血中调节性B细胞CD5^+CD19^+IL-10(B10)表达量的差异,探讨B10在乳腺癌发生、发展中的作用。方法收集50例乳腺癌患者和50例健康体检者外周血,用流式细胞仪检测调节性B细胞的表达情况。结果乳腺癌患者外周血中B10的数量明显高于健康对照者(P<0.05),且Ⅲ-Ⅳ期乳腺癌患者外周血B10的百分率(3.50±0.20)%高于Ⅰ～Ⅱ期的患者(1.85±0.25)%,均高于健康对照组(1.30±0.50)%。结论乳腺癌临床分期越高,B10含量逐渐升高,表明B10细胞与乳腺癌的发展存在着一定的相关性。This study was performed to evaluate the roles of regulatory B cells CD5^+CD19^+IL-10(B10) in the development and progression of breast cancer by detecting the differential expression of B10 in peripheral blood of breast cancer patients and healthy controls. Flow cytometry was employed to detect B10 expression in peripheral blood of 50 patients with breast cancer and 50 healthy controls. Data showed that the amount of B10 in peripheral blood of breast cancer patients was significantly higher than that of healthy control(P<0.05);the percentage of B10 in peripheral blood of breast cancer patients in stage Ⅲ-Ⅳ(3.50±0.20)% was higher than that of patients in stage Ⅲ(1.85±0.25)%, both of which were higher than that of the healthy control group(1.30±0.50)%. In conclusion, the higher the clinical stage of breast cancer is, the higher the content of B10 becomes, which indicating that there is a certain correlation between B10 cells and the development of breast cancer.

关 键 词：乳腺癌 调节性B细胞 B10 IL-10 

分 类 号：R446.19[医药卫生—诊断学]